1

Alberto Noto MD, PhD^{1,2*}, Claudia Crimi MD, PhD³, Andrea Cortegiani^{4,5}, Massimiliano Giardina⁶, Filippo Benedetto⁷, Pietro Princi², Annalisa Carlucci^{8,9}, Lorenzo Appendini¹⁰, Cesare Gregoretti^{4,11}.

¹Department of Human Pathology of the Adult and Evolutive Age "Gaetano Barresi", Division of Anesthesia and Intensive Care, University of Messina, Policlinico "G. Martino", Messina, Italy

²IPCF-CNR, Institute for Chemical and Physical Processes, National Research Council, Messina, Italy

³Respiratory Medicine Unit, "Policlinico-Vittorio Emanuele San Marco" University Hospital, Catania, Italy

⁴Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), University of Palermo, Italy

⁵Department of Anesthesia Intensive Care and Emergency, Policlinico Paolo Giaccone, Palermo, Italy

⁶Anesthesia and Intensive Care, Policlinico "G. Martino", Messina, Italy

⁷Unit of Vascular Surgery, Department of Biomedical, Dental Sciences and Morphofunctional Imaging, Policlinic "G. Martino", University of Messina, Italy

⁸Department of Medicina e Chirurgia Università Insubria Varese-Como, Italy

⁹Pulmonary Rehabilitation Unit, Istituti Clinici Scientifici Maugeri, Pavia, Italy

¹⁰ASL CN1, S.S.D. Fisiopatologia Respiratoria, Ospedale di Saluzzo, Saluzzo (CN), Italy

¹¹G. Giglio Foundation, Cefalù, Italy

Correspondence to:

Alberto Noto, MD, PhD

Department of Human Pathology of the Adult and Evolutive Age

2

"Gaetano Barresi", Division of Anesthesia and Intensive Care,

University of Messina, Policlinico "G. Martino",

Via Consolare Valeria, 1

98100 Messina, Italy

Phone: +390902212450

Email: alberto.noto@unime.it

Keywords:

continuous positive airway pressure; snorkeling face mask; carbon dioxide rebreathing; acute respiratory failure; COVID-19

Word Count:

- Overall: 2951 - Abstract: 222 - Introduction: 276 - Discussion: 1137 **ABSTRACT**

Background: During the COVID-19 pandemic, the need for noninvasive respiratory

support devices has dramatically increased, sometimes exceeding hospital capacity. The

full-face Decathlon snorkeling mask, EasyBreath® (EB® mask), has been adapted to

deliver continuous positive airway pressure (CPAP) as an emergency respiratory interface.

We aimed to assess the performance of this modified EB® mask.

Methods: CPAP set at 5, 10, and 15 cmH₂O was delivered to 10 healthy volunteers with a

high-flow system generator set at 40, 80, and 120 L min⁻¹ and with a turbine-driven

ventilator during both spontaneous and loaded (resistor) breathing. Inspiratory CO₂ partial

pressure (PiCO₂), pressure inside the mask, breathing pattern and electrical activity of the

diaphragm (EAdi) were measured at all combinations of CPAP/flows delivered, with and

without the resistor.

Results: Using the high-flow generator set at 40 L min⁻¹, the PiCO₂ significantly increased

and the system was unable to maintain the target CPAP of 10 and 15 cmH₂O and a stable

pressure within the respiratory cycle; conversely, the turbine-driven ventilator did. EAdi

significantly increased with flow rates of 40 and 80 L min⁻¹ but not at 120 L min⁻¹ and with

the turbine-driven ventilator.

Conclusions: EB[®] mask can be safely used to deliver CPAP only under strict constraints,

using either a high-flow generator at a flow rate greater than 80 L min⁻¹, or a high-

performance turbine-driven ventilator.

Hospitals and physicians worldwide are facing a new health emergency as a consequence of the coronavirus diseases 2019 (COVID-19) pandemic ¹ that has spread enormously worldwide ², placing an extraordinary demand on the health-care systems. Approximately 30% of hospitalized patients with COVID-19 develop acute hypoxemic respiratory failure (AHRF) requiring oxygen and noninvasive respiratory support (NRS). About 5% of them require invasive mechanical ventilation (IMV) and intensive care unit (ICU) admission ³⁻⁵.

Healthcare organizations have proactively implemented several strategies to supply shortages of equipment as demand surges, rationing life-saving treatments such as using shared mechanical ventilation ⁶, establishing ventilator lottery or ventilator triage policies ^{7,8}, and increasing the use of NRS ⁹. To address the high demand for NRS equipment exceeding the capacity, Food and Drug Administration issued an emergency policy allowing the use of home respiratory devices, such as Continuous Positive Airway Pressure (CPAP), as an alternative to life-saving ventilators ¹⁰.

The need to ensure the availability of the highest possible number of CPAP devices also led a group of engineers from northern Italy to build an "emergency ventilator mask", converting full face snorkeling masks into interfaces that can be used to apply CPAP therapy ¹¹. Nevertheless, innovative and potentially life-saving products not previously tested and approved for clinical use can cause serious adverse effects.

Thus, the present study aimed to assess the technical performance of a modified commercial surface snorkeling mask that has been used in COVID-19 patients in delivering CPAP. The aim of this study was to evaluate the stability of pressure generated and the amount of carbon dioxide (CO₂) rebreathing inside the mask during spontaneously and resistive loaded breathing in healthy volunteers.

Ten healthy volunteers (eight males and two females), with age comprised between 27 and 45 years old and a mean body mass index (BMI) of 24 kg/m² completed the study. None of the subjects complained about discomfort or fogging of the interface.

The FiO₂ delivered during CPAP with the flow generator was between 31% and 34%, depending on the flow/PEEP combination. During CPAP delivered with the turbine-driven ventilator, the FiO₂ ranged from 30 to 35%.

The PiCO₂ ranged from 0 to 7 mmHg, depending on the flow/CPAP level combination used (p<0.01, ANOVA for repeated measurements), as shown in Table 1. The highest PiCO₂ was recorded at 40 L min⁻¹ of fresh gas flow with CPAP 15 cmH₂0 and it decreased progressively to 0 (undetectable) as the fresh gas flow increased up to 120 L min⁻¹ or using the turbine-driven ventilator, independently of the CPAP level.

The pressures inside the mask at different flows/PEEP are shown in Table 2 and Figure 3. Target CPAP was not achieved when the oxygen-driven flow generator delivered 40 L min⁻¹. Only the highest flow tested (120 L min⁻¹) allowed the achievement of all the CPAP levels tested (5,10,15 cmH₂O), even if some over-treatment was obtained at CPAP 5 and 10 cmH₂O (+ 119% and + 35%, respectively). By contrast, the turbine-driven ventilator allowed the maintenance of target CPAP levels throughout the protocol.

Table 2 also shows actual CPAP partitioned between the inspiratory and expiratory phase, as referenced to target CPAP. Only the turbine ventilator succeeded in keeping the actual CPAP level close to its target value both at end-expiration and at end-inspiration for all the CPAP levels tested, the pressure difference between end-inspiration and end-expiration being maintained within 2 cmH₂O. Statistically and clinically worse was the performance of the high-flow generator in this task. As a matter of fact, at a flow of 40 L min⁻¹, neither end-inspiratory nor end-expiratory pressures reached the target CPAP. In

contrast, at 80 and 120 L min⁻¹, the actual pressure was above its target level at end-expiration and below it at end-inspiration, with the difference between these two conditions being well above 2 cmH₂O, Table 2. Similar results were obtained for both loaded and unloaded breathing, Table 2.

The respiratory pattern (flows, volume, and respiratory timing) and the EAdi recorded at baseline and at different experimental conditions, with and without the use of the resistor, are shown in Table S1 and Figure 4. In comparison to baseline, minute ventilation remained stable with the CPAP mask at any level of pressure applied during unloaded breathing. By contrast, it significantly decreased during loaded breathing because of a significant reduction of tidal volume. Respiratory rate remained constant throughout the protocol (Table S1).

Diaphragmatic electrical activity increased with any CPAP level compared to baseline, either in terms of EAdi Insp_{AUC} and EAdi/ V_T (Fig. 4). During loaded breathing, EAdi increased by a similar amount in all the conditions tested.

7

DISCUSSION

The present study showed that the use of a modified EB[®] mask coupled with a high-flow generator: 1) induces substantial CO₂ rebreathing when set at a flow rate below 80 L min⁻¹, 2) fails to achieve CPAP levels higher than 5 cmH₂O if set at a flow rate of 40 L min⁻¹ and 3) increases diaphragm's electrical activation (and, hence, diaphragmatic energy expenditure) due to pressure instability along the respiratory cycle. These adverse effects disappear using high flows flushing the CPAP circuit (> 80 L min⁻¹) or a high-performance turbine-driven ventilator set in CPAP mode.

The use of repurposed devices to fend off the shortage of ventilators during the current COVID-19 pandemic, without prior evidence of efficacy, is an issue of increasing concern ¹². Manufacturers are allowed to market many medical devices without the need to provide proof of their effectiveness, especially in urgent unusual circumstances like the COVID-19 pandemic ¹³. Indeed, clinicians may be forced to adopt unregistered interfaces, such as the popular Decathlon EB[®] mask, to deliver ventilatory support to patients with little or no prior tests of performance. To the best of our knowledge, this is the first study that fills this knowledge gap after the introduction of the modified Decathlon EB[®] mask for CPAP delivery.

The use of CPAP in acute hypoxemic respiratory failure has the principal aim to improve gas-exchange increasing the end-expiratory lung volume (EELV) and avoiding at the same time the inspiratory elastic threshold-load imposed by the increased EELV ¹⁴. This task has been effectively accomplished by non-invasively applied CPAP ^{15,16}. However, some interfaces can provoke CO₂ rebreathing if misused, thus impairing treatment effectiveness ¹⁷.

CO₂ rebreathing

EB[®] mask has a wide dead-space (about 800-900 ml), and thus, given a fixed CO₂ production, it requires high flows to wash-out the exhaled CO₂ completely. In accordance with previous findings obtained with other high dead-space interfaces ¹⁷ only CPAP flow rate of 120 L min⁻¹ or flows guaranteed by a high-performance turbine-driven ventilator completely flushed out CO₂. Thus, in case of emergency use of the EB[®] mask, the first caveat is to use very high flows of fresh gas (about fourfold the peak inspiratory flow) in the circuit, whatever its source.

Effectiveness in achieving target CPAP

An ideal CPAP system, by definition, should provide a target positive airway pressure through the respiratory cycle to improve alveolar recruitment and gas exchange. This was not the case of the EB® mask. Our data show that although the pressure inside the mask never dropped below zero during the inspiratory phase, it always remained far below the set CPAP level when using a fresh gas flow of 40 L min⁻¹. On the other hand, during the expiratory phase, the pressure level recorded at the highest rate of fresh gas flow (120 L min⁻¹) overcame the set CPAP level, at least at 5 and 10 cmH₂O, potentially generating an undue increase in end-expiratory lung volume. Fresh gas flow of 80 L min⁻¹ performed in the middle, overcoming the set pressure of 5 cmH₂O and under-assisting at the target CPAP of 15 cmH₂O.

Mechanical ventilators are the most sophisticated devices to administer CPAP.

However, old devices performed worse than high flow generators in delivering stable

CPAP levels, mainly because of the demand-valve technology ¹⁸. The newer generation of ventilators has complex flow algorithms that allow for a more aggressive flow modulation and delivery flows using single circuits with intentional leaks designed to stabilize airway pressure and lessen the imposed work of breathing ¹⁵. This was the case in our study when CPAP was delivered with the turbine-driven ventilator provided with an intentional

leak circuit (EB[®] mask + turbine-ventilator + single circuit + intentional leak), where we recorded a stable pressure at any level of target CPAP tested.

Diaphragmatic activity and effort

An ideal CPAP system should provide a constant positive airway pressure throughout the respiratory cycle to avoid negative effects on the work of breathing 19,20 since large pressure swings around the set PEEP level are associated with increased respiratory efforts ²¹. Our study showed that end-inspiratory to end-expiratory pressure swing was clinically relevant (above 3 cmH₂0) at all set levels of CPAP and flows when using the high flow generator with a flow rate lower that 80 L min⁻¹. We observed this phenomenon notwithstanding the presence of a pressure stabilizer (reservoir bag) and a threshold PEEP valve in the CPAP circuit that should maintain the pressure stable whatever is the flow passing through it. Pressure swings occurring across target CPAP levels imply wasted patients' respiratory effort spent against CPAP device, ineffective in producing flow and volume ¹⁸. As a matter of fact, EAdi inspiratory activity and, hence, diaphragmatic effort ²² increased with CPAP application compared to baseline in all the study conditions (with or without resistive loading) when high flow CPAP generator delivered flows of 40 and 80 L min⁻¹. This result confirms previous data showing increased work of breathing during CPAP application ²³, and suggesting a suboptimal performance of high flow CPAP generators ^{24,25}.

EAdi increase can be due to CPAP system-induced increased workload, on a CO₂ rebreathing-induced increase of respiratory drive, or a combination of both. The inspiratory EAdi-time product (EAdi InspAUC) increased by 45% during CPAP application and only 35% when it was normalized for V_T, indicating that both the above-quoted mechanisms contributed to the overall increase of EAdi activity during EB[®] mask CPAP delivery, as compared to spontaneous breathing. The increase of diaphragmatic electrical activity (and effort) disappeared during CPAP set at the highest flow tested (120 L min⁻¹) and during

CPAP delivered by the turbine ventilator indicating that these constraints should be considered in case of emergency use of the EB[®] mask.

This study should be a warning sign against the indiscriminate use of tools to deliver noninvasive respiratory support without rigorous tests of performance.

Strengths and limitations

The main strength of our study is the rigorous evaluation of several parameters of performance (i.e. PiCO₂, Pmask, EAdi) at three different levels of flow, recreating the setup used in clinics for noninvasive ventilatory support in COVID-19 patients.

The present study has several limitations. First, this was a proof-of-concept study performed in healthy volunteers; therefore, it may not reflect the dynamic nature of ventilation parameters during severe acute respiratory syndrome. However, simulating loaded breathing, we partially overcame this limitation. Furthermore, we did not compare the new device against a 'gold standard'. Thus, up to now, it is only clear that the EB® mask works properly only under strictly controlled conditions. Still, it is impossible to state whether it is inferior/superior to reference interfaces. Finally, the PiCO₂ was stable during the conditions tested, but the recordings lasted only 2 minutes each. Therefore, we cannot ensure that these values would have remained stable for a longer period.

CONCLUSION

The modified Decathlon's EB[®] mask should be used for emergency use to deliver CPAP only under strict constraints, using a high-flow generator at a flow rate greater than 80 L min⁻¹, or with a high-performance turbine-driven ventilator.

METHODS

Study Design

We designed a physiological study involving ten healthy volunteers recruited among physicians at the Department of Anesthesia and Critical Care, Policlinico "G. Martino," University of Messina, Italy, in June 2020. The study was approved by the Ethics committee of Policlinico G. Martino, Messina, Italy (32-30 27/05/2020). All the study participants provided written informed consent.

Experimental set-up and Study devices

The experimental set-up is illustrated in Figure 1. We used a modified Decathlon's EasyBreath® (EB® mask) surface snorkeling mask (Decathlon, Villeneuve-d'Ascq, France) as a full-face mask to deliver CPAP. The original valve set on the chin was modified to be permanently closed, allowing all exhaled air to be evacuated through the two lateral channels of the mask to the top of the snorkel ²⁶. Unlike conventional interfaces used in clinical practice, this mask has two different compartments inside; the upper one for the eyes, dedicated to the vision, and the lower one for the mouth and nose, dedicated to the breathing. The original EB® mask snorkel was replaced with a 3D printed adaptor, the Charlotte valve, patented by ISINNOVA (Brescia, Italy), to connect the mask to an oxygendriven flow generator. This valve has an inlet line connected to the oxygen and an outlet line connected to a threshold resistor [Positive End Expiratory Pressure (PEEP) valve], as shown in Figure S1. The internal volume was measured by filling the mask with water when applied to the volunteers' face, as previously described ²⁷, and amounted to 880±11 ml.

To allow measurements, the experimental setting included the following items (figure 1):

 a pneumotachograph (V.T. mobile; Fluke Biomedical, Everett, WA, USA) to measure ventilatory airflow, connected with a serial interface to a laptop for

- recording (V.T. for Windows Software version 2.01.07, Fluke Biomedical, Everett, WA, USA);
- a side-stream capnometer (CO2SMO plus; Novametrix Medical System,
 Wallingford, Connecticut, USA) to measure inspiratory carbon dioxide tension
 (PiCO₂);
- 3) a dedicated nasogastric tube with a built-in multiple array esophageal electrode (Edicatheter) to monitor diaphragm activity ¹⁴. It was connected to a Servo-I ventilator (Getinge, Solna, Sweden), equipped with Neurally Adjusted Ventilatory Assist (NAVA) (Getinge, Solna, Sweden), linked through a serial interface to a laptop with dedicated software (Servo-tracker version 4.2, Getinge, Solna, Sweden).
- 4) a pressure transducer (coupled to the V.T. mobile, through an auxiliary port) to measure the pressure inside the mask (Pmask) connected to the laptop for recording.

All the instruments underwent testing and calibration according to the manufacturers' specifications before performing all the measurements.

Measurements and recordings

Based on the experimental set-up, the following variables were measured: 1) PiCO₂; 2) Minute ventilation; 3) Pmask; 4) electrical diaphragm activity (EAdi).

Each volunteer was studied placed comfortably in a semi-recumbent position and performed all the tests on the same day in random order. Volunteers were first allowed to adapt to CPAP breathing before the recordings.

At baseline, two, 120 seconds each, recordings of breathing pattern and EAdi were carried out without the mask. The first one during quiet unloaded breathing, and the second while breathing through an inline resistor (connected to the mouthpiece) made with an endotracheal tube connector with an inner diameter of 5 mm, to simulate an increase of respiratory load.

After tightly fitting to the volunteers' face the modified EB[®] mask ¹¹, leaks were minimized by sealing the mask chin valve around all measurement lines. Two sets of measurements were performed while delivering CPAP with two different systems:

- 1) a CPAP flow generator (Whisperflow 2, Respironics), connected to the 3D printed Charlotte valve ¹¹ attached to the mask. A reservoir bag inserted in the inspiratory line was used to minimize airway pressure variations. An adjustable PEEP valve (Ambu, Denmark) added to the Charlotte valve's expiratory port provided the PEEP level. PiCO₂, Pmask, flow lines, and the Edi catheter were inserted into the mask through the sealed chin valve (Figure 1). CPAP was set at three different flow rates (40, 80, 120 L min⁻¹) and for each flow, three different PEEP levels were employed (5, 10, 15 cmH₂O), with and without the resistor in place (*load*);
- 2) a turbine-driven home care mechanical ventilator (Astral 150, Resmed, San Diego, USA) set in CPAP mode at three different PEEP levels: 5, 10, 15 cmH₂0. CPAP was administered with a single limb vented configuration with an intentional leak (a tube connector with an inner diameter of 5.5 mm) placed on the Charlotte valve's expiratory port. Low-pressure oxygen was provided to the turbine-driven ventilator through a dedicated port in order to obtain the same FiO₂ used to drive the flow generator.

A 120 seconds-trial was recorded for each session for off-line analysis. No instructions were given to the subjects regarding the breathing pattern to adopt.

Data analysis

A Matlab (version 9.7.0.1190202, The MathWorks Inc., Natick, Massachusetts, USA) automatic procedure was developed to find maximal and minimum EAdi (Figure 2) and pressure for each breath. The EAdi-time product, measured as the EAdi curve area from the beginning to the end of an inspiratory cycle (EAdi Insp_{AUC}), was calculated

(Figure 2). The EAdi Insp_{AUC} was then normalized for the tidal volume (V_T), (EAdi / V_T). Average end-expiration and end-inspiration peak pressures were calculated for every recording session. The same was also done for the EAdi_{max}, EAdi Insp_{AUC}, and EAdi / V_T . For each recording session, the average delta pressure inside the mask at the end-expiration (Δ Pmask Exp = Pmask end-expiratory – CPAP Level) and end-inspiration (Δ Pmask Insp = Pmask end-inspiratory - CPAP Level) were computed.

The distribution of each continuous variable was initially tested with the Shapiro-Wilk test for normality. Results are expressed as mean \pm SD when normally distributed, otherwise as median and interquartile range. Based on preliminary measurements, we estimated that 10 healthy subjects were necessary to detect, with a 0.8 power, a significant difference (α = .05) on airway pressure drop during inspiration (Δ Pmask Insp). Comparisons of Δ Pmask at different flows and for each CPAP level were assessed using the analysis of variance (ANOVA) for repeated measures. The statistical analysis was performed using (SPSS 24, IBM) software. A p value < .05 was considered significant.

References

- 1 WHO. Coronavirus disease (COVID-2019) Situation Report 2020, https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen> (2020).
- 2 Dashboard by the center for systems science and engineering (CSSE) at Johns Hopkins University., https://gisanddata.maps.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd4029 9423467b48e9ecf6> (2020).
- 3 WHO. Coronavirus disease 2019 (COVID-19) situation report 38. World Health Organization, Geneva https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200227-sitrep-38-covid-19.pdf?sfvrsn=9f98940c (2020).
- 4 Huang, C. *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* **395**, 497-506, doi:10.1016/S0140-6736(20)30183-5 (2020).
- 5 Wang, D. *et al.* Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*, doi:10.1001/jama.2020.1585 (2020).
- 6 Herrmann, J., Fonseca da Cruz, A., Hawley, M. L., Branson, R. D. & Kaczka, D. W. Shared Ventilation in the Era of COVID-19: A Theoretical Consideration of the Dangers and Potential Solutions. *Respir Care*, doi:10.4187/respcare.07919 (2020).
- 7 Silva, D. S. Ventilators-by-Lottery: The Least Unjust Form of Allocation in the COVID-19 Pandemic. *Chest*, doi:10.1016/j.chest.2020.04.049 (2020).
- 8 Emanuel, E. J. *et al.* Fair Allocation of Scarce Medical Resources in the Time of Covid-19. *N Engl J Med* **382**, 2049-2055, doi:10.1056/NEJMsb2005114 (2020).
- 9 Crimi, C. *et al.* Noninvasive respiratory support in acute hypoxemic respiratory failure associated with COVID-19 and other viral infections. *Minerva Anestesiol*, doi:10.23736/S0375-9393.20.14785-0 (2020).
- 10 FDA, U. S. Enforcement Policy for Ventilators and Accessories and Other Respiratory Devices During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency, https://www.fda.gov/emergency-preparedness-and-response/mcm-issues/coronavirus-disease-2019-covid-19 (2020).
- 11 Mauri, T. *et al.* Physiologic Effects of High-Flow Nasal Cannula in Acute Hypoxemic Respiratory Failure. *Am J Respir Crit Care Med* **195**, 1207-1215, doi:10.1164/rccm.201605-0916OC (2017).
- 12 Wilkes, A. R., Hodzovic, I. & Latto, I. P. Introducing new anaesthetic equipment into clinical practice. *Anaesthesia* **63**, 571-575, doi:10.1111/j.1365-2044.2008.05583.x (2008).
- 13 French-Mowat, E. & Burnett, J. How are medical devices regulated in the European Union? *J R Soc Med* **105 Suppl 1**, S22-28, doi:10.1258/jrsm.2012.120036 (2012).
- 14 Beck, J., Sinderby, C., Lindstrom, L. & Grassino, A. Crural diaphragm activation during dynamic contractions at various inspiratory flow rates. *J Appl Physiol* (1985) **85**, 451-458, doi:10.1152/jappl.1998.85.2.451 (1998).
- 15 Volsko, T. A. Devices Used for CPAP Delivery. *Respir Care* **64**, 723-734, doi:10.4187/respcare.06625 (2019).

- 16 Cortegiani, A. *et al.* A New Configuration for Helmet Continuous Positive Airway Pressure Allowing Tidal Volume Monitoring. *Am J Respir Crit Care Med* **202**, 612-614, doi:10.1164/rccm.202003-0550LE (2020).
- 17 Racca, F. *et al.* Helmet ventilation and carbon dioxide rebreathing: effects of adding a leak at the helmet ports. *Intensive Care Med* **34**, 1461-1468, doi:10.1007/s00134-008-1120-x (2008).
- 18 Gibney, R. T., Wilson, R. S. & Pontoppidan, H. Comparison of work of breathing on high gas flow and demand valve continuous positive airway pressure systems. *Chest* **82**, 692-695, doi:10.1378/chest.82.6.692 (1982).
- 19 Venus, B., Jacobs, H. K. & Lim, L. Treatment of the adult respiratory distress syndrome with continuous positive airway pressure. *Chest* **76**, 257-261, doi:10.1378/chest.76.3.257 (1979).
- 20 Ricksten, S. E., Bengtsson, A., Soderberg, C., Thorden, M. & Kvist, H. Effects of periodic positive airway pressure by mask on postoperative pulmonary function. *Chest* **89**, 774-781, doi:10.1378/chest.89.6.774 (1986).
- 21 Mistraletti, G. *et al.* Noninvasive CPAP with face mask: comparison among new air-entrainment masks and the Boussignac valve. *Respir Care* **58**, 305-312, doi:10.4187/respcare.01598 (2013).
- Beck, J. *et al.* Electrical activity of the diaphragm during pressure support ventilation in acute respiratory failure. *Am J Respir Crit Care Med* **164**, 419-424, doi:10.1164/ajrccm.164.3.2009018 (2001).
- Gherini, S., Peters, R. M. & Virgilio, R. W. Mechanical work on the lungs and work of breathing with positive end-expiratory pressure and continuous positive airway pressure. *Chest* **76**, 251-256, doi:10.1378/chest.76.3.251 (1979).
- 24 Glover, G. W. & Fletcher, S. J. Assessing the performance of the Whisperflow continuous positive airway pressure generator: a bench study. *Br J Anaesth* **102**, 875-881, doi:10.1093/bja/aep077 (2009).
- Vargas, M. *et al.* Performances of CPAP Devices With an Oronasal Mask. *Respir Care* **63**, 1033-1039, doi:10.4187/respcare.05930 (2018).
- 26 Kroo, L. *et al.* Pneumask: Modified Full-Face Snorkel Masks as Reusable Personal Protective Equipment for Hospital Personnel. *medRxiv* 2020.04.24.20078907, doi: https://doi.org/10.1101/2020.04.24.20078907 (2020).
- Fraticelli, A. T. *et al.* Physiological effects of different interfaces during noninvasive ventilation for acute respiratory failure. *Crit Care Med* **37**, 939-945, doi:10.1097/CCM.0b013e31819b575f (2009).

17

Acknowledgements:

The authors express gratitude to Prof. G. Risitano for the 3D print of the Charlotte Valve and to M.L. Noto for assistance in the drawing.

Financial Disclosure: None.

Conflict of interest:

Prof. Alberto Noto received honoraria for lectures from Edwards Lifescience (not relevant to this protocol).

Dr. Cortegiani declares a patent pending, in association with the University of Palermo – Italy (N°102019000020532) – Italian Ministry of Economic Development), not discussed in the present study.

Prof. Cesare Gregoretti declares a patent pending, in association with the University of Palermo – Italy (N°102019000020532) – Italian Ministry of Economic Development), not discussed in the present study. Prof. Gregoretti received honoraria for lectures or consultancies from Philips, Resmed, Vivisol, OrionPharma, Origin (not relevant to this protocol).

All other authors declare no competing interests.

Authors' contributions:

A.N., C.G. and C.C, conceived and designed the study.

A.N., P.P., M.G. and F.B. collected the data.

A.N. and P.P., developed the data analysis tools.

A.N., P.P., A.C., A.Ca., L.A. performed the analysis.

A.N., C.C., L.A., C.G. wrote the manuscript.

All authors have critically revised the manuscript and approved the final version.

CPAP LEVEL (cmH₂0)	40 L min ⁻¹ mean (SD)	80 L min ⁻¹ mean (SD)	120 L min ⁻¹ mean (SD)	Astral 150 mean (SD)	p value	
5	5 (0.9)	1.2 (0.7)	0 (0)	0 (0)	<0.01	
10	6.5 (1.3)	1.9 (0.8)	0 (0)	0 (0)	<0.01	
15	7 (1.5)	3.2 (1.4)	0 (0)	0 (0)	<0.01	

Table 1. Inspiratory CO₂ partial pressure at different flow rate and PEEP level.

Abbreviations: CPAP, continuous positive airway pressure; SD, standard deviation; PEEP, Positive End Expiratory Pressure; Astral 150: turbine-driven ventilator.

 $\ensuremath{\mathsf{p}}$ value ANOVA for repeated measures (same CPAP level with different flow).

CPAP LEVEL (cmH ₂ 0)	P mask	40 L min ⁻¹		80 L min ⁻¹		120 L min ⁻¹		Astral 150		p value	
	mean (SD)	load		load		load		load		load	
	(cmH₂0)	off	on	off	on	off	on	off	on	off	on
5	End Exp	4.7	4.6	9.7	9.7	11.1	10.8	6.1	6.2	< 0.01	< 0.01
		(2.3)*	(2.2)*	(2.4)*	(2.1)*	(3.4)*	(3.8)*	(2.7)	(2.7)		
	End Insp	2.1	2.1	6.7	7	7.7	7.7	4.3	4.6	< 0.01	< 0.01
		(2.3)*	(2.3)*	(2.6)*	(2.2)*	(2.6)*	(3.1)*	(2.7)	(2.8)		
10	End Exp	4.8	4.8	12.3	11.9	13.7	13.3	10.8	10.9	< 0.01	< 0.01
		(2.4)*	(2.2)*	(2.2)*	(2.2)	(4.0)*	(4.4)*	(2.8)	(2.8)		
	End Insp	2.1	2.2	8.4	8.5	10.1	9.8	8.6	9	< 0.01	< 0.01
		(2.4)*	(2.6)*	(2.7)	(2.4)	(3.5)*	(3.8)	(2.8)	(2.7)		
15	End Exp	5.4	4.9	14.9	14.6	16.0	16.2	15.7	15.6	< 0.01	< 0.01
		(2.8)*	(2.2)*	(3.3)	(3.2)	(4.3)	(4.8)	(2.7)	(2.8)		
	End Insp	2.0	2.2	9.8	10.2	11.8	12	13.0	13	< 0.01	< 0.01
		(2.4)*	(2.5)*	(3.2)*	(2.9)*	(4.1)	(4.4)	(2.6)	(2.8)		

Table 2. Pressure recorded inside the mask (P mask) during different experimental settings.

Abbreviations: CPAP, continuous positive airway pressure; SD, standard deviation; End Exp, end-expiratory; End Insp, end-inspiratory; load, tube connector with inner diameter of 5 mm; Astral 150: turbine-driven ventilator.

^{*:} Significant difference compared to Astral 150 (Within-Subjects Contrast); p value: repeated measures ANOVA (same CPAP level at different flow).

Figure legends

Figure 1: Experimental setup.

Abbreviations: CPAP, continuous positive airway pressure; PEEP, Positive End Expiration Pressure.

Figure 2: Matlab automatic EAdi analysis.

Abbreviations: EAdi, electrical diaphragm activity; EAdi_{max}, peak electrical diaphragm activity; EAdi_{min}, electrical diaphragm activity; EAdi Insp_{AUC}, electrical diaphragm activity area of the inspiratory phase; EAdi Tin, inspiratory time derived from electrical diaphragm activity; EAdi Ttot, total respiratory time derived from electrical diaphragm activity.

Figure 3: Pressure recorded inside the mask.

Upper whiskers represent the mean pressure at end-expiration; Lower whiskers represent the mean pressure at end-inspiration; Circles represent the mean pressure; Redline represents the set CPAP level.

Figure 4: Electrical diaphragm effort.

EAdi/V_T, electrical diaphragm activity area of the inspiratory phase normalized for the tidal volume (V_T); EAdi Insp_{AUC}, electrical diaphragm activity area of the inspiratory phase.







